• Abstract
• Full-Text PDF [468 KB]
• Full-Text XML
• Article Versions Notes

• Article Statistics
• PubMed/Medline
• Google Scholar
• Order Reprints

• Cite this article
• Export to BibTeX
• Export to EndNote

• [+] on DOAJ
• Liu, Y
• Zhang, B
• Yan, B
• [+] on Google Scholar
• Liu, Y
• Zhang, B
• Yan, B
• [+] on PubMed
• Liu, Y
• Zhang, B
• Yan, B

•  CiteULike
•  Facebook
•  Mendeley
•  Twitter

This article is

• freely available
• re-usable

Int. J. Mol. Sci. 2011, 12(7), 4395-4413; doi:10.3390/ijms12074395

Review

Enabling Anticancer Therapeutics by Nanoparticle Carriers: The Delivery of Paclitaxel

Yongjin Liu ¹ , Bin Zhang ¹  and Bing Yan ^1,2,*

¹ School of Chemistry and Chemical Engineering, Shandong University, Jinan 250100, China ² St. Jude Children’s Research Hospital, Memphis, TN 38105, USA

* Author to whom correspondence should be addressed.

Received: 27 April 2011; in revised form: 9 June 2011 / Accepted: 15 June 2011 / Published: 7 July 2011

(This article belongs to the Special Issue Bioactive Nanoparticles)

Download PDF Full-Text [468 KB, uploaded 7 July 2011 13:52 CEST]

Abstract: Anticancer drugs, such as paclitaxel (PTX), are indispensable for the treatment of a variety of malignancies. However, the application of most drugs is greatly limited by the low water solubility, poor permeability, or high efflux from cells. Nanoparticles have been widely investigated to enable drug delivery due to their low toxicity, sustained drug release, molecular targeting, and additional therapeutic and imaging functions. This review takes paclitaxel as an example and compares different nanoparticle-based delivery systems for their effectiveness in cancer chemotherapy.

Keywords: nanomaterials; anticancer drugs; paclitaxel; drug carrier; drug delivery

Article Statistics

Cite This Article